Our application will address the need for diagnostics to discriminate common flu-like pathogens from bioterrorist agents. Our approach is to use microarrays to detect changes in blood cell RNA within hours of exposure. Sets of genes will be identified that discriminate one pathogen from another, and these genes will be used to make a small microarray to further streamline diagnosis. Such an approach will eliminate the need to wait for symptoms or for pathogen replication. ? Within hours of exposure to a pathogen, white blood cells respond by altering their gene expression. RNA from white blood cells will be transcribed into cDNA and hybridized to standardized gene microarrays that monitor changes in cellular mRNA expression. Although the majority of the responses are non-specific (such as interferon responses to pathogen nucleic acid), an important subset is specific and potentially diagnostic for discriminating between exposure to one pathogen and another. Preliminary data demonstrate specific gene expression patterns in response to several bioterrorist agents. We will use cultured human lymphocytes: monocytes (4:1) to monitor mRNA responses to 4 different viruses causing flu-like symptoms (Influenza A, Parainfluenza 1, Rhinovirus, and Respiratory Syncytial virus). We will establish a database of gene expression responses that are diagnostic and specific for those viruses. These findings will be validated by comparison with gene expression in PBMC from human subjects. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI053620-02
Application #
6658119
Study Section
Special Emphasis Panel (ZAI1-AC-M (M1))
Program Officer
Lacourciere, Karen A
Project Start
2002-09-15
Project End
2005-08-31
Budget Start
2003-09-01
Budget End
2005-08-31
Support Year
2
Fiscal Year
2003
Total Cost
$198,500
Indirect Cost
Name
University of MD Biotechnology Institute
Department
Type
Organized Research Units
DUNS #
603819210
City
Baltimore
State
MD
Country
United States
Zip Code
21202
Zapata, Juan C; Salvato, Maria S (2015) Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man. Future Virol 10:233-256
Zapata, Juan Carlos; Carrion Jr, Ricardo; Patterson, Jean L et al. (2013) Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate. PLoS Negl Trop Dis 7:e2406
GarcĂ­a, C C; Topisirovic, I; Djavani, M et al. (2010) An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem Biophys Res Commun 393:625-30
Rodas, Juan D; Cairo, Cristiana; Djavani, Mahmoud et al. (2009) Circulating natural killer and gammadelta T cells decrease soon after infection of rhesus macaques with lymphocytic choriomeningitis virus. Mem Inst Oswaldo Cruz 104:583-91
Djavani, Mahmoud; Crasta, Oswald R; Zhang, Yan et al. (2009) Gene expression in primate liver during viral hemorrhagic fever. Virol J 6:20
Lukashevich, Igor S; Carrion Jr, Ricardo; Salvato, Maria S et al. (2008) Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26:5246-54
Carrion Jr, Ricardo; Patterson, Jean L; Johnson, Curtis et al. (2007) A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25:4093-102
Giacalone, Matthew J; Zapata, Juan C; Berkley, Neil L et al. (2007) Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus. Vaccine 25:2279-87
Djavani, Mahmoud M; Crasta, Oswald R; Zapata, Juan Carlos et al. (2007) Early blood profiles of virus infection in a monkey model for Lassa fever. J Virol 81:7960-73
Garcia, Cybele C; Djavani, Mahmoud; Topisirovic, Ivan et al. (2006) Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. J Gen Virol 87:1217-28

Showing the most recent 10 out of 12 publications